IL33 and myeloid sarcoma: Several groups have directly demonstrated that ILC2 activity in the brain is downregulated in many instances of neurodegenerative damage (e.g., aging, AD, MS, SCI)49,50,64 and that ILC2 activation via IL-33 supplementation can attenuate cognitive decline55.